Table 1.
Association between antihypertensive use and outcome of COVID-19 patients with hypertension comorbidity.
| Unadjusted | Adjusteda | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics | Total patients | Survival | Death | OR | 95% CI | P value | OR | 95% CI | P value | |
| All cases, n (%) | 655 | 619 | 36 | |||||||
| No use | 69 (10.5) | 62 (10.0) | 7 (19.4) | Ref. | Ref. | Ref. | Ref. | |||
| ARB | 149 (22.7) | 146 (23.6) | 3 (8.3) | 0.182 | 0.046-0.727 | 0.013 | 0.421 | 0.19–0.934 | 0.033 | |
| ACEI | 44 (6.7) | 43 (6.9) | 1 (2.8) | 0.206 | 0.024–1.735 | 0.147 | 0.497 | 0.184–1.34 | 0.168 | |
| Thiazide | 38 (5.8) | 33 (5.3) | 5 (13.9) | 1.342 | 0.395–4.559 | 0.751 | 0.992 | 0.666–1.477 | 0.968 | |
| BB | 100 (15.3) | 97 (15.7) | 3 (8.3) | 0.274 | 0.068–1.099 | 0.093 | 0.496 | 0.268–0.919 | 0.026 | |
| CCB | 441 (67.3) | 420 (67.9) | 21 (5.8) | 0.443 | 0.181–1.085 | 0.084 | 0.34 | 0.119–0.968 | 0.043 | |
| Older than 65 years, n (%) | 318 | 292 | 26 | |||||||
| No use | 31 (9.7) | 25 (8.6) | 6 (23.1) | Ref. | Ref. | Ref. | Ref. | |||
| ARB | 78 (24.5) | 76 (26.0) | 2 (7.7) | 0.11 | 0.021–0.578 | 0.006 | 0.202 | 0.055–0.745 | 0.016 | |
| ACEI | 19 (6) | 19 (6.5) | 0 (0) | —— | —— | 0.071 | —— | —— | 0.996 | |
| Thiazide | 24 (7.5) | 22 (7.5) | 2 (7.7) | 0.379 | 0.069–2.073 | 0.443 | —— | —— | 0.988 | |
| BB | 54 (17) | 51 (17.5) | 3 (11.5) | 0.245 | 0.057–1.062 | 0.067 | 0.531 | 0.286–0.988 | 0.046 | |
| CCB | 214 (67.3) | 198 (67.8) | 16 (61.5) | 0.337 | 0.121–0.94 | 0.043 | 0.22 | 0.062–0.778 | 0.019 | |
aFully adjusted model includes the following covariates: age, gender, baseline of blood pressure (including SBP and DBP), and coexisting medical conditions (including chronic heart, lung, renal, liver, and cerebrovascular disease, diabetes, and cancer). Detailed information is shown in Supplementary Tables S5–S6.